On Friday, Athersys, Inc. (NASDAQ:ATHX)’s shares declined -35.78% to $1.40.
Athersys, Inc. (ATHX) declared interim results from its exploratory Phase 2 clinical study of the intravenous administration of MultiStem(R) cell therapy to treat patients who have suffered an ischemic stroke.
The study results demonstrate favorable safety and tolerability for MultiStem, compriseent with preceding studies. With respect to the primary and secondary endpoints, the cell therapy did not show a difference at 90 days contrast to placebo. However, MultiStem treatment was associated with lower rates of mortality and life threatening adverse events (AEs), infections and pulmonary events. Furthermore, post-hoc analysis shows that patients who received MultiStem treatment earlier in the treatment window had more robust recovery rates in comparison to placebo and relative to patients who received later MultiStem treatment.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has accomplished Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-as compared to-host disease.
Discovery Laboratories, Inc. (NASDAQ:DSCO)’s shares dropped -18.84% to $1.12.
Discovery Laboratories, Inc. (DSCO) declared that it has accomplished enrollment in its AEROSURF® phase 2a clinical trial assessing the administration of a single dose of AEROSURF in premature infants 29-34 week gestational age (GA) with respiratory distress syndrome (RDS).
The company also is implementing a restructuring plan to voluntarily cease the commercialization of SURFAXIN® (lucinactant) Intratracheal Suspension and focus its resources on the development of its aerosolized KL4 surfactant for respiratory diseases, startning with AEROSURF.
Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), in addition to develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant.
At the end of Friday’s trade, ForceField Energy Inc (NASDAQ:FNRG)‘s shares dipped -16.24% to $3.97.
ForceField Energy Inc (FNRG) requested that a regulatory agency review the trading activity in its common stock subsequent to the issuance of a lengthy “opinion” published by MoxReports on April 15, 2015; in addition to any relationships, arrangements and commonalities between short sellers and others.
The opinion was written by an individual investor, not a registered financial advisor, who has revealed owning a short position in the Company’s common stock. The Company maintains that the article contains material inaccuracies about its administration, business and prospects.
ForceField Energy Inc., through its auxiliaries, designs, distributes, and licenses alternative energy products and technologies in China and the United States. It distributes light emitting diode (LED) commercial lighting products and fixtures; and produces trichlorosilane, a chemical used for the production of polysilicon that is utilized as a raw material in the production of solar cells for photovoltaic panels.
GenMark Diagnostics, Inc (NASDAQ:GNMK), ended its Friday’s trading session with -15.68% loss, and closed at $10.86.
GenMark Diagnostics, Inc (GNMK) declared positive preliminary first quarter 2015 results, and an update on the commercial launch of its ePlex sample-to-answer system.
First quarter 2015 revenue is predictable to be $10.1 million, a raise of 28% over the preceding year period. During the quarter, 22 additional XT-8 analyzers were placed in end-user laboratories, resulting in a total installed base of 562 analyzers within the U.S. market.
GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products comprise XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
